Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 18 December 1987:
Vol. 238. no. 4834, pp. 1704 - 1707
DOI: 10.1126/science.3500514
Prev | Table of Contents | Next

Articles

Science, Vol 238, Issue 4834, 1704-1707
Copyright © 1987 by American Association for the Advancement of Science

articles

Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen

DH Smith, RA Byrn, SA Marsters, T Gregory, JE Groopman, and DJ Capon

Department of Molecular Biology, Genentech, Inc., South San Francisco, CA 94080.

The initial event in the infection of human T lymphocytes, macrophages, and other cells by human immunodeficiency virus (HIV-1) is the attachment of the HIV-1 envelope glycoprotein gp120 to its cellular receptor, CD4. As a step toward designing antagonists of this binding event, soluble, secreted forms of CD4 were produced by transfection of mammalian cells with vectors encoding versions of CD4 lacking its transmembrane and cytoplasmic domains. The soluble CD4 so produced binds gp120 with an affinity and specificity comparable to intact CD4 and is capable of neutralizing the infectivity of HIV-1. These studies reveal that the high-affinity CD4-gp120 interaction does not require other cell or viral components and may establish a novel basis for therapeutic intervention in the acquired immune deficiency syndrome (AIDS).


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Human Immunodeficiency Virus Type 1 Escape from Cyclotriazadisulfonamide-Induced CD4-Targeted Entry Inhibition Is Associated with Increased Neutralizing Antibody Susceptibility.
K. Vermeire, K. Van Laethem, W. Janssens, T. W. Bell, and D. Schols (2009)
J. Virol. 83, 9577-9583
   Abstract »    Full Text »    PDF »
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.
J. Zhou, P. Swiderski, H. Li, J. Zhang, C. P. Neff, R. Akkina, and J. J. Rossi (2009)
Nucleic Acids Res. 37, 3094-3109
   Abstract »    Full Text »    PDF »
From the Cover: Neutralization of HIV-1 by redirection of natural antibodies.
M. F. Perdomo, M. Levi, M. Sallberg, and A. Vahlne (2008)
PNAS 105, 12515-12520
   Abstract »    Full Text »    PDF »
Impact of Natural Polymorphism within the gp41 Cytoplasmic Tail of Human Immunodeficiency Virus Type 1 on the Intracellular Distribution of Envelope Glycoproteins and Viral Assembly.
M. Lambele, B. Labrosse, E. Roch, A. Moreau, B. Verrier, F. Barin, P. Roingeard, F. Mammano, and D. Brand (2007)
J. Virol. 81, 125-140
   Abstract »    Full Text »    PDF »
Inhibition of HIV-1 Replication by Amphotericin B Methyl Ester: SELECTION FOR RESISTANT VARIANTS.
A. A. Waheed, S. D. Ablan, M. K. Mankowski, J. E. Cummins, R. G. Ptak, C. P. Schaffner, and E. O. Freed (2006)
J. Biol. Chem. 281, 28699-28711
   Abstract »    Full Text »    PDF »
Role of the Stable Signal Peptide and Cytoplasmic Domain of G2 in Regulating Intracellular Transport of the Junin Virus Envelope Glycoprotein Complex.
S. S. Agnihothram, J. York, and J. H. Nunberg (2006)
J. Virol. 80, 5189-5198
   Abstract »    Full Text »    PDF »
A Mutation in the Human Immunodeficiency Virus Type 1 Gag Protein Destabilizes the Interaction of the Envelope Protein Subunits gp120 and gp41.
M. R. Davis, J. Jiang, J. Zhou, E. O. Freed, and C. Aiken (2006)
J. Virol. 80, 2405-2417
   Abstract »    Full Text »    PDF »
Discovery of Small-Molecule Human Immunodeficiency Virus Type 1 Entry Inhibitors That Target the gp120-Binding Domain of CD4.
Q.-e. Yang, A. G. Stephen, J. W. Adelsberger, P. E. Roberts, W. Zhu, M. J. Currens, Y. Feng, B. J. Crise, R. J. Gorelick, A. R. Rein, et al. (2005)
J. Virol. 79, 6122-6133
   Abstract »    Full Text »    PDF »
Nef Stimulates Human Immunodeficiency Virus Type 1 Replication in Primary T Cells by Enhancing Virion-Associated gp120 Levels: Coreceptor-Dependent Requirement for Nef in Viral Replication.
C. A. Lundquist, J. Zhou, and C. Aiken (2004)
J. Virol. 78, 6287-6296
   Abstract »    Full Text »    PDF »
Rapid and Automated Fluorescence-Linked Immunosorbent Assay for High-Throughput Screening of Hiv-1 Fusion Inhibitors Targeting gp41.
S. Liu, L. Boyer-Chatenet, H. Lu, and S. Jiang (2003)
J Biomol Screen 8, 685-693
   Abstract »    PDF »
Specific CD4 down-modulating compounds with potent anti-HIV activity.
K. Vermeire and D. Schols (2003)
J. Leukoc. Biol. 74, 667-675
   Abstract »    Full Text »    PDF »
From the Cover: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
P.-F. Lin, W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y.-F. Gong, H.-G. H. Wang, R. Rose, G. Yamanaka, et al. (2003)
PNAS 100, 11013-11018
   Abstract »    Full Text »    PDF »
Mutations Conferring Resistance to Neutralization by a Soluble Form of the Neurotrophin Receptor (p75NTR) Map outside of the Known Antigenic Sites of the Rabies Virus Glycoprotein.
C. Langevin and C. Tuffereau (2002)
J. Virol. 76, 10756-10765
   Abstract »    Full Text »    PDF »
Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6.
F. Verrier, A. Nadas, M. K. Gorny, and S. Zolla-Pazner (2001)
J. Virol. 75, 9177-9186
   Abstract »    Full Text »    PDF »
Envelope Glycoprotein Determinants of Neutralization Resistance in a Simian-Human Immunodeficiency Virus (SHIV-HXBc2P 3.2) Derived by Passage in Monkeys.
Z. Si, M. Cayabyab, and J. Sodroski (2001)
J. Virol. 75, 4208-4218
   Abstract »    Full Text »    PDF »
Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 Infection by Altering the Position of the gp120 V1/V2 Variable Loops.
P. Kolchinsky, E. Kiprilov, P. Bartley, R. Rubinstein, and J. Sodroski (2001)
J. Virol. 75, 3435-3443
   Abstract »    Full Text »    PDF »
Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants.
P. Kolchinsky, E. Kiprilov, and J. Sodroski (2001)
J. Virol. 75, 2041-2050
   Abstract »    Full Text »    PDF »
Identification of Key Residues in Subgroup A Avian Leukosis Virus Envelope Determining Receptor Binding Affinity and Infectivity of Cells Expressing Chicken or Quail Tva Receptor.
S. L. Holmen, D. C. Melder, and M. J. Federspiel (2001)
J. Virol. 75, 726-737
   Abstract »    Full Text »    PDF »
Octamerization Enables Soluble CD46 Receptor To Neutralize Measles Virus In Vitro and In Vivo.
D. Christiansen, P. Devaux, B. Reveil, A. Evlashev, B. Horvat, J. Lamy, C. Rabourdin-Combe, J. H. M. Cohen, and D. Gerlier (2000)
J. Virol. 74, 4672-4678
   Abstract »    Full Text »    PDF »
Adaptation of a CCR5-Using, Primary Human Immunodeficiency Virus Type 1 Isolate for CD4-Independent Replication.
P. Kolchinsky, T. Mirzabekov, M. Farzan, E. Kiprilov, M. Cayabyab, L. J. Mooney, H. Choe, and J. Sodroski (1999)
J. Virol. 73, 8120-8126
   Abstract »    Full Text »    PDF »
Effects of Soluble CD4 on Simian Immunodeficiency Virus Infection of CD4-Positive and CD4-Negative Cells.
D. Schenten, L. Marcon, G. B. Karlsson, C. Parolin, T. Kodama, N. Gerard, and J. Sodroski (1999)
J. Virol. 73, 5373-5380
   Abstract »    Full Text »    PDF »
Production and Characterization of a Soluble, Active Form of Tva, the Subgroup A Avian Sarcoma and Leukosis Virus Receptor.
J. W. Balliet, J. Berson, C. M. D'Cruz, J. Huang, J. Crane, J. M. Gilbert, and P. Bates (1999)
J. Virol. 73, 3054-3061
   Abstract »    Full Text »    PDF »
Synthetic Peptides Derived from the Variable Regions of an Anti-CD4 Monoclonal Antibody Bind to CD4 and Inhibit HIV-1 Promoter Activation in Virus-infected Cells.
C. Monnet, D. Laune, J. Laroche-Traineau, M. Biard-Piechaczyk, L. Briant, C. Bes, M. Pugniere, J.-C. Mani, B. Pau, M. Cerutti, et al. (1999)
J. Biol. Chem. 274, 3789-3796
   Abstract »    Full Text »    PDF »
Continued Utilization of CCR5 Coreceptor by a Newly Derived T-Cell Line-Adapted Isolate of Human Immunodeficiency Virus Type 1.
K. E. Follis, M. Trahey, R. A. LaCasse, and J. H. Nunberg (1998)
J. Virol. 72, 7603-7608
   Abstract »    Full Text »    PDF »
Receptor-Binding Properties of a Soluble Form of Human Cytomegalovirus Glycoprotein B.
K. A. Boyle and T. Compton (1998)
J. Virol. 72, 1826-1833
   Abstract »    Full Text »    PDF »
Coreceptor Utilization by Human Immunodeficiency Virus Type 1 Is Not a Primary Determinant of Neutralization Sensitivity.
R. A. Lacasse, K. E. Follis, T. Moudgil, M. Trahey, J. M. Binley, V. Planelles, S. Zolla-Pazner, and J. H. Nunberg (1998)
J. Virol. 72, 2491-2495
   Abstract »    Full Text »    PDF »
Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic Rats.
C. Renard, O. Chappey, M.-P. Wautier, M. Nagashima, E. Lundh, J. Morser, L. Zhao, A.-M. Schmidt, J.-M. Scherrmann, and J.-L. Wautier (1997)
Mol. Pharmacol. 52, 54-62
   Abstract »    Full Text »
The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection.
E. O. Freed and M. A. Martin (1995)
J. Biol. Chem. 270, 23883-23886
   Full Text »    PDF »
Therapy for Human Immunodeficiency Virus Infection.
M. S. Hirsch and R. T. D'Aquila (1993)
N. Engl. J. Med. 328, 1686-1695
   Full Text »
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
S. Hwang, T. Boyle, H. Lyerly, and B. Cullen (1992)
Science 257, 535-537
   Abstract »    PDF »
Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than With Azidothymidine.
M. K. Sachs (1992)
Arch Intern Med 152, 485-501
   Abstract »    PDF »
The Pharmacological Treatment of Human Immunodeficiency Virus Infection.
R. J. Wong (1992)
Journal of Pharmacy Practice 5, 121-130
   Abstract »    PDF »
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
S. Hwang, T. Boyle, H. Lyerly, and B. Cullen (1991)
Science 253, 71-74
   Abstract »    PDF »
Recombinant Human Soluble CD4 Does Not Inhibit Immune Function in Cynomolgus Monkeys.
P. J. Bugelski, P. A. Thiem, A. Truneh, and D. G. Morgan (1991)
Toxicol Pathol 19, 580-588
   Abstract »    PDF »
Antiretroviral Therapy in AIDS.
S. Broder, H. Mitsuya, R. Yarchoan, and G. N. Pavlakis (1990)
Ann Intern Med 113, 604-618
   Abstract »    PDF »
Molecular targets for AIDS therapy.
H Mitsuya, R Yarchoan, and S Broder (1990)
Science 249, 1533-1544
   Abstract »    PDF »
Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120.
R. Finberg, D. Diamond, D. Mitchell, Y Rosenstein, G Soman, T. Norman, S. Schreiber, and S. Burakoff (1990)
Science 249, 287-291
   Abstract »    PDF »
Enhancement of SIV infection with soluble receptor molecules.
J. Allan, J Strauss, and D. Buck (1990)
Science 247, 1084-1088
   Abstract »    PDF »
Recombinant Soluble CD4 Therapy in Patients with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex: A Phase I-II Escalating Dosage Trial.
R. T. Schooley, T. C. Merigan, P. Gaut, M. S. Hirsch, M. Holodniy, T. Flynn, S. Liu, R. E. Byington, S. Henochowicz, E. Gubish, et al. (1990)
Ann Intern Med 112, 247-253
   Abstract »    PDF »
The Safety and Pharmacokinetics of Recombinant Soluble CD4 (rCD4) in Subjects with the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex: A Phase 1 Study.
J. O. Kahn, J. D. Allan, T. L. Hodges, L. D. Kaplan, C. J. Arri, H. F. Fitch, A. E. Izu, J. Mordenti, S. A. Sherwin, J. E. Groopman, et al. (1990)
Ann Intern Med 112, 254-261
   Abstract »    PDF »
Antiviral Drugs in Pediatrics.
H. H. Balfour Jr and J. A. Englund (1989)
Arch Pediatr Adolesc Med 143, 1307-1316
   Abstract »    PDF »
The MHC-binding and gp120-binding functions of CD4 are separable.
D Lamarre, A Ashkenazi, S Fleury, D. Smith, R. Sekaly, and D. Capon (1989)
Science 245, 743-746
   Abstract »    PDF »
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.
J Homsy, M Meyer, M Tateno, S Clarkson, and J. Levy (1989)
Science 244, 1357-1360
   Abstract »    PDF »
HIV-infected cells are killed by rCD4-ricin A chain.
M. Till, V Ghetie, T Gregory, E. Patzer, J. Porter, J. Uhr, D. Capon, and E. Vitetta (1988)
Science 242, 1166-1168
   Abstract »    PDF »
Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity.
J. Lifson, K. Hwang, P. Nara, B Fraser, M Padgett, N. Dunlop, and L. Eiden (1988)
Science 241, 712-716
   Abstract »    PDF »
Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein.
B. Jameson, P. Rao, L. Kong, B. Hahn, G. Shaw, L. Hood, and S. Kent (1988)
Science 240, 1335-1339
   Abstract »    PDF »
BLOCKING HIV ATTACHMENT TO CELL-SURFACE RECEPTORS.
(1988)
Journal Watch (General) 1988, 7
   Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)